OPKO Health's GAAP loss for 3 months of 2022 was $55.4 million, up 78.1% from $31.1 million in the previous year. Revenue decreased 39.6% to $329.2 million from $545.2 million a year earlier.

OPKO Health's GAAP loss for 2021 was $30.1 million, down 1.6% from $30.6 million in the previous year. Revenue increased 23.7% to $1.775 billion from $1.435 billion a year earlier.

Japanese Ministry of Health has approved NGENLA, a long-acting growth hormone jointly developed by Pfizer and OPKO. The drug is intended to treat short stature caused by growth hormone deficiency without closed epiphyses. NGENLA reduces the frequency of treatment from daily injections to one shot per week.

OPKO Health's GAAP net income for 9M 2021 was $43.6 mln, compared to a loss of $1.7 mln in the previous year. Revenue increased 45.9% to $1.373 billion from $0.941 billion a year earlier.